• Loading stock data...

Senior Leadership

Bridgeway Capital Partners and Bridgeway Capital Partners II principals have extensive and unique experience managing global investments and delivering personalized advice for growth and middle market companies.

Philip Gaucher is the Founder and Manager of Bridgeway Capital Partners LLC, and the Founder and Managing Partner of Bridgeway Capital Partners II LLC. Collectively, BCP and BCPII provide independent investment banking, strategic capital, and advisory services to lower and middle market companies globally.

Prior to founding Bridgeway, Mr. Gaucher was Founder and Managing Partner of Cambrian Capital LLC. Through Cambrian Mr. Gaucher founded, managed, and helped to raise over $550 million for multiple companies in the healthcare and industrial sectors. Prior to founding Cambrian Capital Mr. Gaucher was a portfolio manager for NY-based hedge funds Del Mar Asset Management and Plural Investments, and an analyst for George Weiss Associates (now Weiss Multi-Strategy Advisors). He began his career in investment banking with Bank of America. He is a graduate of Bucknell University cum laude with a B.A. in Economics and a concentration in Finance.

Bradley T. Hildebrand is a Managing Director at Solomon Partners. Prior to joining Solomon, Mr. Hildebrand was a Managing Director at Bridgeway Capital Partners LLC where he assisted in executing the firm’s M&A transactions and lead the firm’s efforts in the Healthcare Services vertical.

Prior to joining Bridgeway Mr. Hildebrand was at Houlihan Lokey focusing on M&A, capital raising and restructurings in the middle market healthcare space with a focus on healthcare services.

Prior to joining Houlihan Lokey in 2013, Mr. Hildebrand worked for Black River Asset Management and Lakepointe Capital Partners on a wide variety of M&A transactions, capital raises and equity investments as both an advisor and a principal across a range of industries including healthcare, agribusiness, energy, industrials and technology.

Mr. Hildebrand holds an MBA with honors in Analytic Finance and Economics from the University of Chicago Booth School of Business and a BS in Finance from the University of Minnesota. He also holds Series 7 and 63 licenses.

Dr. Hantash is an Operational Executive and Chief Scientific Advisor with Bridgeway Capital Partners II. Dr. Hantash is a serial entrepreneur who has successfully founded multiple healthcare companies.

During the course of his career, Dr. Hantash has acquired or launched over a dozen life sciences products in medical devices, diagnostics, small molecule drugs, biomaterials, cosmeceuticals, nutraceuticals, cell therapy, and nanotechnology. In addition, he has served on the founding team of 10 medical device and biotech start-ups, accumulating 18 years of operational experience including executive, BOD, SAB, and consultant roles. Dr. Hantash’s intellectual property has led to the development of several breakthrough medical devices and skin care products and his R&D efforts have led to the completion of 4 acquisitions, over a dozen FDA-approvals, >100 issued and pending patents, >165 scientific peer-reviewed articles, abstracts, and book chapters, and the creation of over $1B of shareholder value.

Dr. Hantash is a 30-year veteran of Regenerative Medicine, conducting pioneering research at Stanford University investigating the mechanisms underlying mesenchymal stem cell immune tolerance. In 2006, based on his Stanford intellectual property, Dr. Hantash founded and serves as Chairman, CEO, & CSO of Escape Therapeutics, a Stanford University spin out based in Silicon Valley focused on creating the world’s first universal, off-the-shelf, stem cell source for human clinical use.

Dr. Hantash started his Life Science career at Abbott Labs, where he developed and successfully launched a hepatitis screening assay. Dr. Hantash then joined Molecular Geriatrics, a neuroscience Biotech start-up founded by nobel laureate Ferid Murad, MD, PhD. His work there contributed to the discovery and patenting of a novel therapeutic drug for Alzheimer’s disease that was sold to Upjohn. Dr. Hantash completed his Dermatology Residency, Postdoctoral training in the Program for Regenerative Medicine, and a prestigious fellowship in the Biodesign Innovation Program at Stanford University. He received his MD and PhD (pharmacology and physiology) from Rutgers University, where he was inducted in the AOA Medical Honor Society and graduated as valedictorian of both his Graduate and Medical School. Dr. Hantash received his BS in Biology and minor in Chemistry from the University of Illinois, where he was the recipient of a Howard Hughes Research Fellowship. He completed his MBA with honors at The Wharton School, University of Pennsylvania, where he was awarded the Price Institute Fellowship for entrepreneurship. He remains intimately involved in humanitarian relief work and is an award-winning poet featured in several books and one audio CD.

Jeff Janda is the Chief Financial Officer for Bridgeway Capital Partners LLC. Mr. Janda possesses over 30 years of experience in accounting, audit, and tax having practiced as a certified public accountant for both large and small firms over the course of his career.

As a CPA, Mr. Janda has worked with a variety of industries including non-profit, manufacturing, real estate, government, financial institutions, health care, and education. His experience includes working on improving operational efficiencies, generally accepted accounting principles (GAAP), internal controls, audit prep and planning and audit field supervision.